Auris Medical is developing novel pharmaceutical products for the treatment of inner ear disorders and central nervous system disorders.

We are focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept studies in 2019. 

In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. Sonsuvi® has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA.

 Auris Medical Pipeline3

1) Dates of key milestones are indicative and subject to change.
ASNHL: Acute Sensorineural Hearing Loss